Holtman Inge R, Bsibsi Malika, Gerritsen Wouter H, Boddeke Hendrikus W G M, Eggen Bart J L, van der Valk Paul, Kipp Markus, van Noort Johannes M, Amor Sandra
Department of Medical Physiology, University of Groningen, University Medical Center Groningen, Groningen, AV, the Netherlands.
Delta Crystallon BV, Beverwijk, ED, the Netherlands.
Glia. 2017 Mar;65(3):460-473. doi: 10.1002/glia.23104. Epub 2017 Jan 7.
The glial stress protein alpha B-crystallin (HSPB5) is an endogenous agonist for Toll-like receptor 2 in CD14 cells. Following systemic administration, HSPB5 acts as a potent inhibitor of neuroinflammation in animal models and reduces lesion development in multiple sclerosis patients. Here, we show that systemically administered HSPB5 rapidly crosses the blood-brain barrier, implicating microglia as additional targets for HSPB5 along with peripheral monocytes and macrophages. To compare key players in the HSPB5-induced protective response of human macrophages and microglia, we applied weighted gene co-expression network analysis on transcript expression data obtained 1 and 4 h after activation. This approach identified networks of genes that are co-expressed in all datasets, thus reducing the complexity of the nonsynchronous waves of transcripts that appear after activation by HSPB5. In both cell types, HSPB5 activates a network of highly connected genes that appear to be functionally equivalent and consistent with the therapeutic effects of HSPB5 in vivo, since both networks include factors that suppress apoptosis, the production of proinflammatory factors, and the development of adaptive immunity. Yet, hub genes at the core of the network in either cell type were strikingly different. They prominently feature the well-known tolerance-promoting programmed-death ligand 1 as a key player in the macrophage response to HSPB5, and the immune-regulatory enzyme cyclooxygenase-2 (COX-2) in that of microglia. This latter finding indicates that despite its reputation as a potential target for nonsteroidal anti-inflammatory drugs, microglial COX-2 plays a central role in the therapeutic effects of HSPB5 during neuroinflammation. GLIA 2017;65:460-473.
胶质细胞应激蛋白αB晶状体蛋白(HSPB5)是CD14细胞中Toll样受体2的内源性激动剂。全身给药后,HSPB5在动物模型中作为神经炎症的有效抑制剂,并减少多发性硬化症患者的病灶发展。在这里,我们表明全身给药的HSPB5能迅速穿过血脑屏障,这意味着小胶质细胞与外周单核细胞和巨噬细胞一样是HSPB5的额外靶点。为了比较HSPB5诱导的人类巨噬细胞和小胶质细胞保护性反应中的关键参与者,我们对激活后1小时和4小时获得的转录本表达数据应用了加权基因共表达网络分析。这种方法识别出了在所有数据集中共表达的基因网络,从而降低了HSPB5激活后出现的转录本非同步波的复杂性。在这两种细胞类型中,HSPB5都激活了一个高度连接的基因网络,这些基因在功能上似乎是等效的,并且与HSPB5在体内的治疗效果一致,因为这两个网络都包括抑制细胞凋亡、促炎因子产生和适应性免疫发展的因子。然而,这两种细胞类型中网络核心的枢纽基因却显著不同。它们的显著特征是,在巨噬细胞对HSPB5的反应中,著名的促进耐受的程序性死亡配体1是关键参与者,而在小胶质细胞的反应中则是免疫调节酶环氧合酶-2(COX-2)。后一发现表明,尽管小胶质细胞COX-2素有作为非甾体抗炎药潜在靶点的名声,但它在神经炎症期间HSPB5的治疗效果中起着核心作用。《胶质细胞》2017年;65:460 - 473。